U.S. Markets closed

Jazz Pharmaceuticals plc (JAZZ)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
144.10-1.53 (-1.05%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close145.63
Open145.50
Bid135.00 x 3200
Ask144.43 x 900
Day's Range143.05 - 146.37
52 Week Range86.88 - 156.26
Volume519,236
Avg. Volume755,330
Market Cap8.098B
Beta (5Y Monthly)1.15
PE Ratio (TTM)61.16
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Benzinga

    Jazz Pharmaceuticals's Earnings: A Preview

    Jazz Pharmaceuticals (NASDAQ: JAZZ) releases its next round of earnings this Monday, November 02. Here is Benzinga's essential guide to Jazz Pharmaceuticals's Q3 earnings report.What Are Earnings, Net Income, And Earnings Per Share? Earnings and EPS are useful metrics of profitability. Total earnings also known as net income is equal to total revenue minus total expenses. Dividing net income by the total number of shares outstanding yields EPS.Earnings And Revenue Wall Street expects EPS of $4.07 and sales around $576.95 million. Jazz Pharmaceuticals reported a profit of $4.1 per share when it published results during the same quarter last year. Sales in that period totaled $537.70 million.What Are Analyst Estimates And Earnings Surprises, And Why Do They Matter? Analysts who cover this company will publish forward-looking estimates of its revenue and EPS each quarter. Averaging together every EPS and revenue prediction that each analyst makes about a company in a quarter yields the "consensus estimates." A company posting earnings or revenue above or below the consensus estimate is known as an "earnings surprise" and may move the stock by a considerable margin.View more earnings on JAZZIf the company were to match the consensus estimate when it reports Monday, EPS would have fallen 0.73%. Revenue would be up 7.3% from the year-ago period. Here is how the company's EPS has stacked up against analyst estimates in the past:Quarter Q2 2020 Q1 2020 Q4 2020 Q3 2019 EPS Estimate 3.11 0.67 4.12 3.59 EPS Actual 3.71 0.45 4.42 4.10 Revenue Estimate 504.65 M 543.59 M 561.69 M 525.16 M Revenue Actual 562.44 M 534.73 M 581.74 M 537.70 M Stock Performance Shares of Jazz Pharmaceuticals were trading at $145.63 as of October 29. Over the last 52-week period, shares are up 12.74%. Given that these returns are generally positive, long-term shareholders should be content going into this earnings release.Do not be surprised to see the stock move on comments made during its conference call. Jazz Pharmaceuticals is scheduled to hold the call at 16:30:00 ET and can be accessed here.See more from Benzinga * Click here for options trades from Benzinga * Preview: SBA Communications's Earnings * Mondelez International's Earnings: A Preview(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Is a Surprise Coming for Jazz Pharmaceuticals (JAZZ) This Earnings Season?
    Zacks

    Is a Surprise Coming for Jazz Pharmaceuticals (JAZZ) This Earnings Season?

    Jazz Pharmaceuticals (JAZZ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • Jazz Pharmaceuticals (JAZZ) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
    Zacks

    Jazz Pharmaceuticals (JAZZ) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

    Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.